The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/II multicenter study of ABI-009 (nab-sirolimus) combined with FOLFOX and bevacizumab as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss.
 
Sunil Sharma
Stock and Other Ownership Interests - Beta Cat Pharmaceuticals; ConverGene; Proteus Digital Health; Salarius Pharmaceuticals; StiL Forschungs; Stingray Therapeutics
Honoraria - ARIAD; Array BioPharma; Blend Therapeutics; Exelixis; Foundation Medicine; Foundation Medicine; Genesis Biotechnology Group; Guardant Health; Guardant Health; Loxo; Novartis; Novartis; US Oncology
Consulting or Advisory Role - LSK BioPharma; Natera
Research Funding - Bayer (Inst); Blueprint Medicines (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Johnson & Johnson (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Onyx (Inst); Plexxikon (Inst); XuanZhu (Inst)
Patents, Royalties, Other Intellectual Property - Patent: “Substituted N-(3-(Pyrimidin-4-YL)Phenyl)Acrylamide Analogs as Tyrosine Receptor Kinase BTK Inhibitors”. U.S. Patent No. 9,206,176. Washington, D.C.:U.S. Patent and Trademark Office.; Patent: Substituted N-(3(Pyrimidin-4-YL)Phenyl)Acrylamide Analogs as Tyrosine Receptor Kinase BTK Inhibitors. U.S. Patent No. US 9,296,703, B2. Washington, D.C.:U.S. Patent and Trademark Office.
Travel, Accommodations, Expenses - BioTherapeutics Delivery Society; Five Prime Therapeutics; HeritX; LSK Biopharma; LSK Biopharma; Translational Genomics Research Institute
 
Carlos Roberto Becerra
Honoraria - Taiho Pharmaceutical
Consulting or Advisory Role - Agenus; Bayer; HERON; Ipsen; SOBI; Takeda
Speakers' Bureau - Bristol-Myers Squibb; Celgene; Celgene; Lilly; Merck Serono; Taiho Pharmaceutical
 
Marc Ryan Matrana
No Relationships to Disclose
 
Angela Tatiana Alistar
Consulting or Advisory Role - Celgene; Rafael Pharmaceuticals
Speakers' Bureau - Bristol-Myers Squibb; Merck
Travel, Accommodations, Expenses - Bristol-Myers Squibb; celgene; Rafa Pharmaceutical
 
E. Gabriela Chiorean
Consulting or Advisory Role - AstraZeneca; Celgene; Exelixis; Five Prime Therapeutics; Genentech/Roche; Halozyme; Ipsen; Vicus Therapeutics
Research Funding - Boehringer Ingelheim (Inst); Celgene (Inst); Ignyta (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Stemline Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Genentech/Roche
 
Anita Nagypal Schmid
Employment - AADi
Stock and Other Ownership Interests - AADi
 
Berta Grigorian
Employment - AADi
Stock and Other Ownership Interests - AADi
 
Shihe Hou
Employment - AADi
Stock and Other Ownership Interests - AADi
 
Neil Desai
Employment - AADi
Leadership - AADi
Stock and Other Ownership Interests - AADi